

# Predictors of Treatment Response in Bipolar Disorders: Evidence From Clinical and Brain Imaging Studies

Terence A. Ketter, M.D., and Po W. Wang, M.D.

The clinical features of bipolar disorders can be correlated with responses to medications. Patients who respond to lithium, for example, often present differently from those who respond to divalproex or carbamazepine, but the correlations are relatively modest. Brain-imaging tools, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), and functional magnetic resonance imaging (fMRI), can relate brain function to clinical features and medication responses. For example, in depression, it appears that prefrontal cortical function is decreased while subcortical anterior paralimbic activity is increased. Preliminary evidence suggests that baseline metabolism increases and decreases in the left insula may be associated with carbamazepine and nimodipine responses, respectively, and that cerebral lithium concentrations may correlate with antimanic effects. Although it is not yet a clinical tool for bipolar disorders, brain imaging provides useful research data to understand the fundamental neurobiology of mood disorders and to more effectively target therapeutics.

(*J Clin Psychiatry* 2002;63[suppl 3]:21–25)

The clinical features of bipolar disorders correlate with responses to medication; however, the modest nature of these correlations limits their clinical utility.<sup>1</sup> This article reviews such correlations and presents preliminary data relating medication responses to brain-imaging data. Although it cannot yet be considered a clinical tool, brain imaging is a powerful research tool to increase our understanding of the neurobiology of mood and its disorders.<sup>2</sup>

## CLINICAL MARKERS OF RESPONSE TO MEDICATION

### Lithium

Clinical markers of lithium responsiveness have been extensively explored. Lithium responsiveness has been associated with euphoric mania,<sup>3–6</sup> a classic pattern of mania followed by depression,<sup>7,8</sup> fewer prior episodes,<sup>9,10</sup> complete recovery between episodes,<sup>11</sup> a personal history of lithium response,<sup>3,12</sup> and a family history of bipolar disorder or lithium response.<sup>13,14</sup> In contrast, rapid cycling,<sup>15–18</sup> dysphoric<sup>19</sup> or mixed-manic episodes,<sup>3–6</sup> a history of at least 3 prior episodes,<sup>9,10</sup> a pattern of depression followed by mania,<sup>7</sup> severe mania,<sup>20,21</sup> and secondary mania<sup>22–25</sup> portend poorer responses to lithium. Adolescents,<sup>26,27</sup> patients with comorbid substance abuse,<sup>28,29</sup> or patients with a personal history of nonresponse to lithium<sup>3</sup> are also less likely to do well on lithium therapy. Finally, occasionally patients stabilized on lithium for extended periods of time may become lithium-resistant after discontinuing the agent and then suffer a relapse.<sup>30,31</sup>

### Divalproex

Many patients with poor response to lithium may respond to divalproex, which is effective in pure,<sup>3</sup> mixed,<sup>3,32</sup> or dysphoric mania.<sup>19,33</sup> Moreover, adolescents,<sup>34</sup> patients with rapid-cycling<sup>3,32</sup> or secondary<sup>23–25</sup>

---


*From the Department of Psychiatry and Behavioral Sciences, Bipolar Disorders Clinic, Stanford University School of Medicine, Stanford, Calif.*

*Based on proceedings of a special symposium of the Canadian Network for Mood and Anxiety Treatments (CANMAT), which was held at the 50th annual meeting of the Canadian Psychiatric Association, October 2000, in Victoria, British Columbia. The symposium was supported by an unrestricted educational grant from Janssen-Ortho Inc.*

*Financial disclosure: Dr. Ketter receives grant research support from, is a consultant for, and receives lecture honoraria from Abbott, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, and Janssen; he is also a consultant for AstraZeneca, Cephalon, Elan, and Shire. Dr. Wang reports no financial or other relationships relevant to the subject of this article.*

*Reprint requests to: Terence A. Ketter, M.D., Department of Psychiatry and Behavioral Sciences, Bipolar Disorders Clinic, Stanford University School of Medicine, Stanford, CA 94305-5273 (e-mail: tketter@leland.stanford.edu).*

**Figure 1. Cerebral Blood Flow and Metabolism in Mood Disorders: Findings of 36 Controlled Studies<sup>a</sup>**



<sup>a</sup>Reprinted with permission from Ketter et al.<sup>44</sup>

bipolar disorder or bipolar disorder combined with concurrent substance abuse,<sup>35</sup> and patients unresponsive to lithium or those who cannot tolerate lithium<sup>3,4</sup> often respond to divalproex.

Previous treatment with antidepressants or stimulants may increase the risk of nonresponse to divalproex. In an open trial by Winsberg et al.,<sup>36</sup> medication-naïve patients had an 82% (9/11) response rate to divalproex, while the response rate among patients who had been treated in the past with antidepressants or stimulants was only 38% (3/8). If these results are borne out, they may indicate that early treatment with mood stabilizers is preferable to early exposure to antidepressants or stimulants.

### Carbamazepine


Clinical markers of response to carbamazepine are similar in some respects to those for response to divalproex, i.e., nonclassical,<sup>8</sup> secondary,<sup>22</sup> lithium-unresponsive, or intolerant patients<sup>37,38</sup> may respond to carbamazepine. However, findings have been less consistent with regard to the predictive value of a rapid-cycling pattern,<sup>18,38-40</sup> dysphoric mania,<sup>41,42</sup> and severe mania.<sup>38,43</sup>

### CAN CLINICAL FEATURES BE CORRELATED WITH BRAIN-IMAGING DATA?

Brain functions, such as cerebral blood flow (CBF) and glucose metabolism (CRMglu), can be measured with tools such as positron emission tomography (PET), single photon emission computed tomography (SPECT), and functional magnetic resonance imaging (fMRI). Cerebral biochemistry can be assessed using PET with specific radioligands and using magnetic resonance spectroscopy (MRS).

Many studies have found that depressed patients have decreased frontal lobe function<sup>44</sup> (see Figure 1). In a

**Figure 2. Cerebral Lithium Concentrations Correlate With Antimanic Responses<sup>a</sup>**



<sup>a</sup>Reprinted with permission from Kato et al.<sup>47</sup>  $r = .64$ ,  $p < .05$ .


recent study,<sup>45</sup> whole brain glucose metabolism was decreased 7.7% in bipolar patients with moderate-to-severe depression, but was not significantly altered in mildly depressed or euthymic bipolar patients. Decreased prefrontal cortical blood flow is also found in depressions secondary to diverse conditions, such as Huntington's chorea, Parkinson's disease, and epilepsy. Hence, decreased prefrontal function may be a final common pathway to depression. Conversely, cerebral activity appears to be increased in the amygdala and other subcortical anterior paralimbic structures in primary depression, and this corticolimbic dysregulation (increased subcortical and decreased prefrontal activity) is consistent with the notion that in depression, affective compared with cognitive processing has increased influence.<sup>46</sup>

### CAN TREATMENT RESPONSES BE CORRELATED WITH BRAIN-IMAGING DATA?

Because lithium has an odd number of electrons, its concentration in the brain can be measured using MRS. Brain lithium concentrations  $\geq 0.2$  mEq/L (which roughly correspond to serum concentrations  $\geq 0.4$  mEq/L) correlated with clinical antimanic responses as measured using the Petterson Mania Rating Scale (PMRS) ( $r = .64$ ;  $p < .05$ ; see Figure 2); the correlation was much weaker between antimanic responses and plasma lithium levels ( $r = .33$ ).<sup>47</sup> Measurements of red blood cell lithium levels correlated poorly with clinical responses and, therefore, appear less useful than measurements of plasma and brain lithium levels.

One recent study<sup>48</sup> found that, compared with healthy control subjects and nonresponders, carbamazepine responders had higher pretreatment whole brain and especially left insular glucose metabolism (see Figure 3). The opposite was true for patients who responded to the

Figure 3. Baseline Cerebral Metabolism Correlates Directly With Carbamazepine Response and Inversely With Nimodipine Response<sup>a</sup>



<sup>a</sup>Adapted with permission from Ketter et al.<sup>48</sup> White regions indicate significant correlations between baseline (pretreatment) cerebral glucose metabolism and response to medications. Left, Carbamazepine response correlates directly with baseline cerebral metabolism (higher baseline metabolism associated with better carbamazepine response) in 26 patients. Right, Nimodipine response correlates inversely with baseline cerebral metabolism (lower baseline metabolism associated with better nimodipine response) in 20 patients. White arrows in top left figure indicate left insular region, which had both positive correlations with carbamazepine response and negative correlations with nimodipine response. These findings were evident for both absolute (top row) and globally normalized (bottom row) metabolism.

calcium channel blocker nimodipine. Divalproex responders may have lower baseline rostral anterior cingulate and medial frontal gyrus cerebral glucose metabolism,<sup>49</sup> while in contrast, unipolar depressed patients who respond to fluoxetine may have higher baseline cerebral glucose metabolism in the rostral anterior cingulate.<sup>50</sup> Thus, complementary baseline differences were observed in the bipolar depression patients who responded to divalproex and the unipolar depression patients who responded to fluoxetine.

However, baseline cerebral glucose metabolism is not a clinical test for medication responsivity, due to limited sensitivity and specificity: for example, occasionally patients with high metabolic rates respond poorly to carbamazepine. However, it may be possible to enhance the predictive value of brain-imaging data by using biochemically specific measures relevant to the illness and to putative mechanisms of action of the medications. For example, plasma  $\gamma$ -aminobutyric acid (GABA) appears to be decreased in bipolar disorders; higher (nearer to normal) levels may predict antimanic<sup>51</sup> and possibly even antidepressant<sup>52</sup> responses to divalproex, a GABAergic agent.

Cerebral GABA appears to be decreased in unipolar<sup>53</sup> but not bipolar<sup>54</sup> depression, and when successfully treated with selective serotonin reuptake inhibitors (SSRIs), uni-

polar patients achieve cerebral GABA levels similar to those of healthy control subjects. In contrast, euthymic bipolar patients taking GABAergic agents (divalproex  $\pm$  gabapentin) have occipital GABA/creatinine levels 60% higher than those of healthy control subjects.<sup>55</sup> Thus, unipolar depressed patients may have low baseline cerebral GABA that is normalized with effective SSRI treatment, while depressed bipolar disorder patients may have near-normal cerebral GABA that needs to rise to supranormal levels to yield euthymic mood. One hypothesis that may account for divalproex response is that patients who respond are those who have higher (closer to normal) baseline cerebral levels of the inhibitory neurotransmitter GABA (and thus lower baseline glucose metabolism), in particular, in the rostral cingulate gyrus. These could be the patients who are more likely to achieve the necessary supranormal GABA levels when they are treated with agents that can increase brain GABA.

Preliminary data of this type provide ample illustration of the potential utility and explanatory power of brain-imaging data in our attempts to understand the fundamental neurobiology of mood disorders and, thus, to more effectively target therapeutics.

*Drug names:* carbamazepine (Tegretol and others), divalproex (Depakote), fluoxetine (Prozac and others), gabapentin (Neurontin), nimodipine (Nimotop).

## REFERENCES

1. Goodnick PJ. Predictors of Treatment Response in Mood Disorders. Washington, DC: American Psychiatric Press; 1995
2. Ketter TA, George MS, Kimbrell TA, et al. Functional brain imaging, limbic function, and affective disorders. *Neuroscientist* 1996;2:55–65
3. Bowden CL, Brugger AM, Swann A., et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. Depakote Mania Study Group. *JAMA* 1994;271:918–924
4. Keller MB, Lavori PW, Coryell W, et al. Differential outcome of pure manic, mixed/cycling, and pure depressive episodes in patients with bipolar illness. *JAMA* 1986;255:3138–3142
5. Prien RF, Himmelhoch JM, Kupfer DJ. Treatment of mixed mania. *J Affect Disord* 1988;15:9–15
6. Secunda SK, Katz MM, Swann A, et al. Mania: diagnosis, state measurement and prediction of treatment response. *J Affect Disord* 1985;8: 113–121
7. Maj M, Pirozzi R, Starace F. Previous pattern of course of the illness as a predictor of response to lithium prophylaxis in bipolar patients. *J Affect Disord* 1989;17:237–241
8. Greil W, Kleindienst N, Erazo N, et al. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. *J Clin Psychopharmacol* 1998;18:455–460
9. Gelenberg AJ, Kane JM, Keller MB, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. *N Engl J Med* 1989;321:1489–1493
10. Swann AC, Bowden CL, Calabrese JR, et al. Mania: differential effects of previous depressive and manic episodes on response to treatment. *Acta Psychiatr Scand* 2000;101:444–451
11. Grof P, Alda M, Grof E, et al. The challenge of predicting response to stabilizing lithium treatment: the importance of patient selection. *Br J Psychiatry* 1993;163(suppl 21):16–19
12. Tondo L, Baldessarini RJ, Floris G, et al. Effectiveness of restarting lithium treatment after its discontinuation in bipolar I and bipolar II disorders. *Am J Psychiatry* 1997;154:548–550
13. Maj M, Del Vecchio M, Starace F, et al. Prediction of affective psychoses response to lithium prophylaxis: the role of socio-demographic, clinical, psychological and biological variables. *Acta Psychiatr Scand* 1984;69: 37–44
14. Mendlewicz J, Fieve RR, Stallone F. Relationship between the effectiveness of lithium therapy and family history. *Am J Psychiatry* 1973;130: 1011–1013
15. Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. *Arch Gen Psychiatry* 1974;30:229–233
16. Dunner DL, Fleiss JL, Fieve RR. The course of development of mania in patients with recurrent depression. *Am J Psychiatry* 1976;133:905–908
17. Goodnick PJ, Fieve RR, Schlegel A, et al. Predictors of interepisode symptoms and relapse in affective disorder patients treated with lithium carbonate. *Am J Psychiatry* 1987;144:367–369
18. Okuma T. Effects of carbamazepine and lithium on affective disorders. *Neuropsychobiology* 1993;27:138–145
19. Swann AC, Bowden CL, Morris D, et al. Depression during mania: treatment response to lithium or divalproex. *Arch Gen Psychiatry* 1997;54: 37–42
20. Garfinkel PE, Stancer HC, Persad E. A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania. *J Affective Disord* 1980;2:279–288
21. Swann AC, Secunda SK, Katz MM, et al. Lithium treatment of mania: clinical characteristics, specificity of symptom change, and outcome. *Psychiatry Res* 1986;18:127–141
22. Himmelhoch JM, Garfinkel ME. Sources of lithium resistance in mixed mania. *Psychopharmacol Bull* 1986;22:613–620
23. Kahn D, Stevenson E, Douglas CJ. Effect of sodium valproate in three patients with organic brain syndromes. *Am J Psychiatry* 1988;145:1010–1011
24. Sovner R. The use of valproate in the treatment of mentally retarded persons with typical and atypical bipolar disorders. *J Clin Psychiatry* 1989; 50(3, suppl):40–43
25. Stoll AL, Banov M, Kolbrenner M, et al. Neurologic factors predict a favorable valproate response in bipolar and schizoaffective disorders. *J Clin Psychopharmacol* 1994;14:311–313
26. Carlson GA, Davenport YB, Jamison K. A comparison of outcome in adolescent- and later-onset bipolar manic-depressive illness. *Am J Psychiatry* 1977;134:919–922
27. Strober M, Morrell W, Burroughs J, et al. A family study of bipolar I disorder in adolescence: early onset of symptoms linked to increased familial loading and lithium resistance. *J Affect Disord* 1988;15:255–268
28. Albanese MJ, Bartel RL, Bruno RF, et al. Comparison of measures used to determine substance abuse in an inpatient psychiatric population. *Am J Psychiatry* 1994;151:1077–1078
29. Pond SM, Becker CE, Vandervoort R, et al. An evaluation of the effects of lithium in the treatment of chronic alcoholism, I: clinical results. *Alcohol Clin Exp Res* 1981;5:247–251
30. Maj M, Pirozzi R, Magliano L. Nonresponse to reinstated lithium prophylaxis in previously responsive bipolar patients: prevalence and predictors. *Am J Psychiatry* 1995;152:1810–1811
31. Post RM, Leverich GS, Altshuler L, et al. Lithium-discontinuation-induced refractoriness: preliminary observations. *Am J Psychiatry* 1992;149: 1727–1729
32. Calabrese JR, Woynshville MJ, Kimmel SE, et al. Predictors of valproate response in bipolar rapid cycling. *J Clin Psychopharmacol* 1993;13: 280–283
33. Freeman TW, Clothier JL, Pazzaglia P, et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. *Am J Psychiatry* 1992;149:108–111
34. Papatheodorou G, Kutcher SP. Divalproex sodium treatment in late adolescent and young adult acute mania. *Psychopharmacol Bull* 1993;29: 213–219
35. Brady KT, Sonne SC, Anton R, et al. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. *J Clin Psychiatry* 1995;56:118–121
36. Winsberg ME, DeGolia SG, Strong CM, et al. Divalproex therapy in medication-naïve and mood stabilizer-naïve bipolar II depression. *J Affect Disord*. In press
37. Okuma T, Inanaga K, Otsuki S, et al. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. *Psychopharmacology (Berl)* 1979;66:211–217
38. Post RM, Uhde TW, Roy-Byrne PP, et al. Correlates of antimanic response to carbamazepine. *Psychiatry Res* 1987;21:71–83
39. Dilsaver SC, Swann AC, Shoaib AM, et al. The manic syndrome: factors which may predict a patient's response to lithium, carbamazepine and valproate. *J Psychiatry Neurosci* 1993;18:61–66
40. Joyce PR. Carbamazepine in rapid cycling bipolar affective disorder. *Int Clin Psychopharmacol* 1988;3:123–129
41. Post RM, Rubinow DR, Uhde TW, et al. Dysphoric mania: clinical and biological correlates. *Arch Gen Psychiatry* 1989;46:353–358
42. Luszkat RM, Murphy DP, Nunn CM. Carbamazepine vs lithium in the treatment and prophylaxis of mania. *Br J Psychiatry* 1988;153:198–204
43. Small JG, Klapper MH, Milstein V, et al. Carbamazepine compared with lithium in the treatment of mania. *Arch Gen Psychiatry* 1991;48:915–921
44. Ketter TA, George MS, Kimbrell TA, et al. Neuroanatomical models and brain imaging studies. In: Ioffe RT, Young LT, eds. *Bipolar Disorder: Neurobiology and Clinical Applications*. New York, NY: Marcel Dekker; 1997:179–217
45. Ketter TA, Kimbrell TA, George MS, et al. Effects of mood and subtype on cerebral glucose metabolism in treatment-refractory bipolar disorders. *Biol Psychiatry* 2001;49:97–109
46. Mayberg HS. Limbic-cortical dysregulation: a proposed model of depression. *J Neuropsychiatry Clin Neurosci* 1997;9:471–481
47. Kato T, Inubushi T, Takahashi S. Relationship of lithium concentrations in the brain measured by lithium-7 magnetic resonance spectroscopy to treatment response in mania. *J Clin Psychopharmacol* 1994;14:330–335
48. Ketter TA, Kimbrell TA, George MS, et al. Baseline cerebral hypermetabolism associated with carbamazepine response, and hypometabolism with nimodipine response in mood disorders. *Biol Psychiatry* 1999;46: 1364–1374
49. Ketter TA, Wang PW, Winsberg ME, et al. Baseline hypofrontality and divalproex response in bipolar disorders. *Biol Psychiatry* 2000;47 (8, suppl):126S. Abstract 412
50. Mayberg HS, Brannan SK, Mahurin RK, et al. Cingulate function in depression: a potential predictor of treatment response. *Neuroreport* 1997; 8:1057–1061
51. Petty F, Rush AJ, Davis JM, et al. Plasma GABA predicts acute response to divalproex in mania. *Biol Psychiatry* 1996;39:278–284
52. Ketter TA, Wang PW, Santosa CM, et al. Baseline cerebral glucose metabolism compared to other potential divalproex response markers. In: *New*

- Research Abstracts of the 153rd Annual Meeting of the American Psychiatric Association; May 17, 2000; Chicago, Ill. Abstract NR447:178
53. Sanacora G, Mason GF, Rothman DL, et al. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. *Arch Gen Psychiatry* 1999;56:1043–1047
54. Mason GF, Sanacora G, Anand A, et al. Cortical GABA reduced in unipolar but not bipolar depression. *Biol Psychiatry* 2000;47(8, suppl):92S. Abstract 304
55. Wang PW, Sachs N, Sailasuta N, et al. 3 Tesla <sup>1</sup>H-magnetic resonance spectroscopic (MRS) detection of cerebral gamma-aminobutyric acid (GABA) in bipolar disorder patients and healthy volunteers. *Biol Psychiatry* 2000; 47(8, suppl):27S. Abstract 93

© Copyright 2002 Physicians Postgraduate Press, Inc.  
One personal copy may be printed